Two Multicenter, Randomized, Double-Blind, Parallel Group Comparison Studies of a Novel Foam Formulation of Halobetasol Propionate, 0.05% vs Its Vehicle in Adult Subjects With Plaque Psoriasis

被引:0
|
作者
Bhatia, Neal [1 ]
Gold, Linda Stein [2 ]
Kircik, Leon H. [3 ,4 ,5 ,6 ,7 ]
Schreiber, Rhonda [8 ]
机构
[1] Therapeut Clin Res, San Diego, CA 92161 USA
[2] Henry Ford Hlth Syst, Detroit, MI USA
[3] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[4] Indiana Univ, Med Ctr, Indianapolis, IN 46204 USA
[5] Phys Skin Care PLLC, Louisville, KY USA
[6] DermResearch PLLC, Louisville, KY USA
[7] Skin Sci PLLC, Louisville, KY USA
[8] Mayne Pharma LLC, Raleigh, NC USA
关键词
OINTMENT; CREAM;
D O I
暂无
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: A novel foam formulation of halobetasol propionate, 0.05% (HBP-Foam) has been developed to treat plaque psoriasis in patients who prefer a thermostable topical foam with low application shear that allows for easier coverage over large and/or hirsute areas than existing formulations. Objective:To determine the safety and effectiveness of HBP-Foam in subjects with plaque psoriasis. Methods: Two randomized, double-blind, vehicle-controlled clinical studies were conducted in 560 adult subjects with moderate to severe plaque psoriasis. Subjects applied the assigned test article to all psoriatic plaques twice daily for 14 days. The key efficacy measures were the proportion of subjects with "treatment success," defined as those subjects that achieved a score of 0 (clear) or 1 (almost clear) and at least a two-grade improvement compared to baseline for the Investigator's Global Assessment (IGA) and for the clinical signs of psoriasis (plaque elevation, scaling, and erythema) as well as pruritus. Safety measurements included adverse events and local skin reactions in the treatment area. Results: HBP-Foam was statistically superior to vehicle in achieving "Treatment Success" in 25.3% and 30.7% vs 3.9% and 74% (P<0.001) in Studies 1 and 2, respectively. Pruritus scores statistically improved by over 30% in HBP-Foam treated subjects. In addition, these subjects experienced a significant reduction in the clinical signs of psoriasis (plaque elevation, scaling, and erythema). In contrast, in the vehicle groups the decrease in psoriasis-related signs was generally not observed. Safety outcomes were unremarkable and similar in both the HBP-Foam and vehicle treatment groups. Conclusions:These results demonstrate the safety and effectiveness of HBP-Foam in the treatment of plaque psoriasis. Furthermore, this novel foam formulation has demonstrable for its ease of application over large and/or hairy treatment areas.
引用
收藏
页码:790 / 796
页数:7
相关论文
共 50 条
  • [21] A Comparison of Cyclosporine 0.05% Ophthalmic Emulsion Versus Vehicle in Chinese Patients with Moderate to Severe Dry Eye Disease: An Eight-Week, Multicenter, Randomized, Double-Blind, Parallel-Group Trial
    Chen, Minjie
    Gong, Lan
    Sun, Xinghuai
    Xie, Hanping
    Zhang, Yueqin
    Zou, Liuhe
    Qu, Jia
    Li, Yumin
    He, Jia
    JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2010, 26 (04) : 361 - 366
  • [22] A DOUBLE-BLIND, MULTICENTER, PARALLEL-GROUP TRIAL WITH 0.05-PERCENT HALOBETASOL PROPIONATE OINTMENT VERSUS 0.1-PERCENT DIFLUCORTOLONE VALERATE OINTMENT IN PATIENTS WITH SEVERE, CHRONIC ATOPIC-DERMATITIS OR LICHEN SIMPLEX CHRONICUS
    BRUNNER, N
    YAWALKAR, S
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1991, 25 (06) : 1160 - 1163
  • [23] Efficacy and safety of topical brepocitinib cream for mild-to-moderate chronic plaque psoriasis: a phase IIb randomized double-blind vehicle-controlled parallel-group study
    Landis, Megan N.
    Smith, Stacy R.
    Berstein, Gabriel
    Fetterly, Gerald
    Ghosh, Pranab
    Feng, Gang
    Pradhan, Vivek
    Aggarwal, Sudeepta
    Banfield, Christopher
    Peeva, Elena
    Vincent, Michael S.
    Beebe, Jean S.
    Tarabar, Sanela
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 189 (01) : 33 - 41
  • [24] Efficacy and safety of acitretin plus pioglitazone vs. acitretin plus placebo in patients with severe plaque-type psoriasis: a randomized, double-blind, parallel-group clinical trial
    Mittal, R.
    Pandhi, P.
    Kaur, I.
    Dogra, S.
    Malhotra, S.
    BRITISH JOURNAL OF DERMATOLOGY, 2008, 159 : 65 - 65
  • [25] Novel Topical Esmolol Hydrochloride (Galnobax) for Diabetic Foot Wound: Phase 1/2, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Parallel-Group Study
    Rastogi, Ashu
    Kulkarni, Sudhir A.
    Deshpande, Supreet K.
    Driver, Vickie
    Barman, Hemanga
    Bal, Arun
    Deshmukh, Manisha
    Nair, Harikrishna
    ADVANCES IN WOUND CARE, 2023, 12 (08) : 429 - 439
  • [26] Multicenter, randomized, parallel-group, double-blind, vehicle-controlled study to evaluate the efficacy and safety of PEP005 (ingenol mebutate) gel, 0.05% in patients with actinic keratoses on nonhead locations
    Swanson, Neil
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2010, 62 (03) : AB2 - AB2
  • [27] Effects of tazarotene 0.1% cream in the treatment of facial acne vulgaris: Pooled results from two multicenter, double-blind, randomized, vehicle-controlled, parallel-group trials
    Shalita, AR
    Berson, DS
    Thiboutot, DM
    Leyden, JJ
    Parizadeh, D
    Sefton, J
    Walker, PS
    Gibson, JR
    CLINICAL THERAPEUTICS, 2004, 26 (11) : 1865 - 1873
  • [28] Assessing the Interchangeability of AVT02 and Humira® in Participants with Moderate‑to‑Severe Chronic Plaque Psoriasis: Pharmacokinetics, Efficacy, Safety, and Immunogenicity Results from a Multicenter, Double-Blind, Randomized, Parallel-Group Study
    Steven R. Feldman
    Richard Kay
    Nataliya Reznichenko
    Joanna Sobierska
    Roshan Dias
    Hendrik Otto
    Halimu N. Haliduola
    Abid Sattar
    Ruth Ruffieux
    Heimo Stroissnig
    Fausto Berti
    BioDrugs, 2023, 37 : 551 - 567
  • [29] Second Multicenter, Randomized, Double-blind, Parallel-group Evaluation of Effectiveness and Safety of Intravesical Sodium Chondroitin Sulfate Compared With Inactive Vehicle Control in Subjects With Interstitial Cystitis/Bladder Pain Syndrome
    Nickel, J. Curtis
    Hanno, Philip
    Kumar, Keshava
    Thomas, Heather
    UROLOGY, 2012, 79 (06) : 1220 - 1224
  • [30] Clinic blood pressure responses to two Amlodipine salt formulations, adipate and besylate, in adult Korean patients with mild to moderate hypertension: A multicenter, randomized, double-blind, parallel-group, 8-week comparison
    Lee, HY
    Kang, HJ
    Koo, BK
    Oh, BH
    Kang, HS
    Kim, KS
    Seo, HS
    Ro, YM
    Kang, JH
    Woong, C
    Joo, SJ
    Kim, MH
    Shin, JH
    Yoon, J
    Park, SH
    Jeong, JO
    Ju, AK
    Rhim, CY
    Yeon, KY
    Park, KM
    Lim, DK
    Park, SY
    CLINICAL THERAPEUTICS, 2005, 27 (06) : 728 - 739